Clinical trial
Rasagiline 1 mg and 2 mg Added to Aricept 10 mg Daily in Patients With Mild to…
NCT00104273 · Teva Branded Pharmaceutical Products R&D, Inc., Industry · Completed
Key facts
| NCT number | NCT00104273 |
|---|---|
| Title | Rasagiline 1 mg and 2 mg Added to Aricept 10 mg Daily in Patients With Mild to Moderate Alzheimer's Disease (AD) |
| Official title | A 1-Year, Double-Blind, Randomized, Placebo-Controlled, Study of Rasagiline 1 mg and 2 mg Added to Aricept 10 mg Daily in Patients With Mild to Moderate Dementia of the Alzheimer's Type |
| Lead sponsor | Teva Branded Pharmaceutical Products R&D, Inc., Industry |
| Collaborators | Eisai Inc. Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Dementia, Alzheimer's Disease |
| Intervention type | Drug |
| Interventions | Rasagiline |
| Enrollment | 376 |
| Start date | Aug 1, 2004 |
| Primary completion | Mar 1, 2007 |
| First posted | Feb 25, 2005 |
| Last update posted | Jul 15, 2009 |
| Countries | Australia, Canada, South Africa, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: